Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimacimab
- Development stage
- Phase 2
- Lead developer
- Skye Bioscience
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Nimacimab is a first-in-class humanized monoclonal antibody developed by Skye Bioscience. It acts as a negative allosteric modulator of the cannabinoid CB1 receptor, selectively inhibiting CB1 signaling in the periphery while avoiding central nervous system (CNS) exposure. This mechanism aims to deliver anti-fibrotic, anti-inflammatory, and metabolic benefits without the neuropsychiatric side effects associated with earlier small molecule CB1 antagonists. Nimacimab is being investigated for obesity, chronic kidney disease, non-alcoholic steatohepatitis (NASH), diabetic gastroparesis, and diabetic nephropathies. Preclinical and early clinical studies have shown favorable safety profiles and promising efficacy signals in weight loss and metabolic parameters[2][5][6][7].
- Other names
- Namacizumab
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on nimacimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimacimab.